Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012

Informa Life Sciences has over a decade-long experience in hosting Immunogenicity conferences in the US and Europe and is pleased to present the inaugural Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012. The ONLY event of its kind in the region, researched with and designed for the community of scientists driving progress and innovation in immunogenicity studies in the region. Bringing you global best practices and case studies, teamed with emerging local knowledge, this event will assist you in formulating solutions to your top immunogenicity challenges.

This comprehensive programme will provide you with a detailed insight to the immunogenicity field, including the underlying causes and implications of immunogenicity, current international developments and best practices in immunogenicity risk assessment, prediction, assay development and regulatory expectations and particular considerations for immunogenicity in the Asian region.

5 Reasons to Attend Asia Immunogenicity 2012:

-The ONLY event of its kind in Asia - A ‘must attend’ event given the rapid development of the biotech industry in Asia
-The region’s first to market event highlighting strategies for immunogenicity testing and critical advice to predict and manage unwanted immunogenicity
-Immunogenicity is a major bottleneck in the discovery and development of biotherapeutics – Don’t miss this first event in Asia that will provide you with strategies to predict and manage the immunogenicity response
-Bringing together a multidisciplinary audience this event will provide strategies from preclinical through to clinical to understand, predict and minimize the risk of an immunogenic response
-Regulatory guidances for immunogenicity are unclear – Don’t miss your opportunity to hear a regulatory perspective about minimum data requirements for FDA/EU approval

Who Should Attend


A Multidiscipli